| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/01/2004 | WO2004012700A3 Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release |
| 04/01/2004 | WO2004012699A3 Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent |
| 04/01/2004 | WO2004011054A3 Injectable multimodal polymer depot compositions and uses thereof |
| 04/01/2004 | WO2004009445A9 Packaging and dispensing of rapid dissolve dosage form |
| 04/01/2004 | WO2004009123A3 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/01/2004 | WO2004006884A3 Process for providing a stable crystalline form of salbutamol |
| 04/01/2004 | WO2004005306A3 Metallic object with a nucleic acid coating and derivatives thereof and method for producing said object |
| 04/01/2004 | WO2004004639A3 A novel stable formulation |
| 04/01/2004 | WO2004002399A3 Use of gaba-c receptor antagonists for the treatment of myopia |
| 04/01/2004 | WO2003106536A3 Heat-sensitive polymers and heat reversible gels derived therefrom |
| 04/01/2004 | WO2003105767A3 Antifungal parenteral products |
| 04/01/2004 | WO2003104402A3 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 04/01/2004 | WO2003099830A3 Cardiolipin compositions, methods of preparation and use |
| 04/01/2004 | WO2003099281A3 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 04/01/2004 | WO2003099256A3 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES) |
| 04/01/2004 | WO2003094909A3 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease |
| 04/01/2004 | WO2003094905A8 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
| 04/01/2004 | WO2003092767A3 A method for inhibiting platelet aggregation |
| 04/01/2004 | WO2003091337A8 New polyarylates for drug delivery and tissue engineering |
| 04/01/2004 | WO2003087220A3 Solid emulsions based on thermoplastic elastomers |
| 04/01/2004 | WO2003084518A3 Oral suspension of active principle microcapsules |
| 04/01/2004 | WO2003084517A3 Oral suspension of amoxicillin capsules |
| 04/01/2004 | WO2003084481A3 Biological affinity based delivery systems |
| 04/01/2004 | WO2003075834A3 Activated protein c formulations |
| 04/01/2004 | WO2003074022A3 Emulsion containing hydrophobic nanodrops with bound hemoglobin molecules in a hydrophilic phase as a blood substitute |
| 04/01/2004 | WO2003070227A9 Taste-masked film-type or wafer-type medicinal preparation |
| 04/01/2004 | WO2003066021A3 Drug nanoparticles with lysozyme surface stabiliser |
| 04/01/2004 | WO2003049675A3 Treating muscle wasting with selective androgen receptor modulators |
| 04/01/2004 | WO2003028692A8 Acne treatment using oleanolic acid |
| 04/01/2004 | WO2003009842A8 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/01/2004 | WO2002072870A3 Dry solid medium for storage and analysis of genetic material |
| 04/01/2004 | WO2002064131A3 Inflammation-inhibiting compounds |
| 04/01/2004 | US20040064133 Implantable sensor method and system |
| 04/01/2004 | US20040064127 Method and device for enhanced delivery of a biologically active agent through the spinal spaces into the central nervous system of a mammal |
| 04/01/2004 | US20040064058 Methods and instruments for treating pseudoarthrosis |
| 04/01/2004 | US20040063927 Production of carrageenan and carrageenan products |
| 04/01/2004 | US20040063917 Modified erythropoietin (epo) with reduced immunogenicity |
| 04/01/2004 | US20040063916 Bactericides; antibiotics |
| 04/01/2004 | US20040063912 Comprises interferon-immunoglobulin fusion protein for use in aerosol delivery of therapeutics for treatment or prevention of disease |
| 04/01/2004 | US20040063905 Armed peptides |
| 04/01/2004 | US20040063886 Water-soluble or water-swellable crosslinked copolymers |
| 04/01/2004 | US20040063881 Zwitterionic polymers |
| 04/01/2004 | US20040063794 Vehicle for topical delivery of anti-inflammatory compounds |
| 04/01/2004 | US20040063791 Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions |
| 04/01/2004 | US20040063785 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 04/01/2004 | US20040063722 Antifungal ketoconazole composition for topical use |
| 04/01/2004 | US20040063717 Employing fatty acid oxidation inhibitor; lowering HbA1c, glucose, total cholesterol and/or triglyceride plasma levels; increasing high density lipoprotein concentration; minimizing side effects; ranolazine |
| 04/01/2004 | US20040063689 Compositions containing alpha-2-adrenergic agonist components |
| 04/01/2004 | US20040063678 Dexamethasone Gel |
| 04/01/2004 | US20040063676 Asthma symptomatic relief; formoterol and budesonide |
| 04/01/2004 | US20040063664 Simethicone containing tablet composition and method |
| 04/01/2004 | US20040063663 Acylated cyclodextrin: guest molecule inclusion complexes |
| 04/01/2004 | US20040063655 Antisense modulation of transforming growth factor-beta expression |
| 04/01/2004 | US20040063654 Attenuating expression of target gene in vivo; altering cell growth, survival and/or differentiation; stable respiratory formulation for pulmonary or nasal delivery |
| 04/01/2004 | US20040063647 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 04/01/2004 | US20040063639 Storage stable buffered liquid and lyophilized materials |
| 04/01/2004 | US20040063637 Aqueous formulation of fusion inhibitor and polyol; minimizes number of injections and site reaction |
| 04/01/2004 | US20040063634 Modified kertinocyte growth factor (kgf) with reduced immunogenicity |
| 04/01/2004 | US20040063628 Active agent delivery systems and methods for protecting and administering active agents |
| 04/01/2004 | US20040063626 Use of cyclosporin a 7-thioamide derivatives for hair growth |
| 04/01/2004 | US20040063623 Formulation of boronic acid compounds |
| 04/01/2004 | US20040063615 For therapy of diabetes |
| 04/01/2004 | US20040063611 Comprising levothyroxine sodium, gelatine and fillers, which is free of organic solvent residues |
| 04/01/2004 | US20040063607 Process to improve stability of a pharmaceutical composition |
| 04/01/2004 | US20040063200 Biological component comprising artificial membrane |
| 04/01/2004 | US20040063135 Comprises oligonucleotides for determining concentration of glucuonidase in cell culture; detection and monitoring of malignancies and metastasis; targeted drug delivery |
| 04/01/2004 | US20040062855 Edible PGA coating composition |
| 04/01/2004 | US20040062843 Molecular press dehydration method for vegetative tissue using the solid phase of water soluble polymer substances as a dehydrating agent |
| 04/01/2004 | US20040062824 Composition for treating chronic venous insufficiencies using an extract of red vine leaves |
| 04/01/2004 | US20040062819 Insertion catheter into cerebrospinal fluid; administering drug |
| 04/01/2004 | US20040062815 Bdellosomes |
| 04/01/2004 | US20040062814 Migration control substance absorbs binder liquid; gelation; three-dimensional printing of barrier zone in powder bed |
| 04/01/2004 | US20040062812 Drug in mixture of matrix forming polymer and ion exchange resin |
| 04/01/2004 | US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer |
| 04/01/2004 | US20040062806 Process |
| 04/01/2004 | US20040062805 Pregelatinized starch in a controlled release formulation |
| 04/01/2004 | US20040062804 Multilayer; active materials, core, shell |
| 04/01/2004 | US20040062803 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 04/01/2004 | US20040062802 Maximizing effectiveness of substances used to improve health and well being |
| 04/01/2004 | US20040062801 Drug delivery device containing neuraminidase inhibitor and an H1 antagonist |
| 04/01/2004 | US20040062800 Compressed matrix tablet; mixture of drug and swellable polymer; side effect reduction |
| 04/01/2004 | US20040062799 Therapeutic composition and delivery system for administering drug |
| 04/01/2004 | US20040062797 Controlling particle sizes; high speed degradation of liposomes releasing active materials |
| 04/01/2004 | US20040062796 Enteric administering; anticancer, antiulcer agents; drug with bioadhesive ligand |
| 04/01/2004 | US20040062795 Skin disorders; removal corn, callus; backing containing medical patches |
| 04/01/2004 | US20040062794 Flexible backing; adhesive coating; transdermal supplying; reducing triglyceride concentration; sustained release |
| 04/01/2004 | US20040062791 Ion triggerable, cationic polymers, a method of making same and items using same |
| 04/01/2004 | US20040062778 Surface dissolution and/or bulk erosion controlled release compositions and devices |
| 04/01/2004 | US20040062773 Compositions for the delivery of antigens |
| 04/01/2004 | US20040062759 Polymeric patch containing enzyme; absorber |
| 04/01/2004 | US20040062749 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity |
| 04/01/2004 | US20040062743 Mixture with film forming polymer |
| 04/01/2004 | US20040062733 Subunguicide, and method for treating onychomycosis |
| 04/01/2004 | US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials |
| 04/01/2004 | US20040062722 Aerosol delivery of insulin; absorption by lung tissue; determination of glucose concentration in blood; calibrating dosage of insulin |
| 04/01/2004 | US20040062721 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| 04/01/2004 | US20040062720 Mixture of corticosterone, cosolvent, propellant and antioxidant; respiratory system disorders |
| 04/01/2004 | US20040062719 Carrier for drug delivery; crystal structure core with surface coating; induce crystallization of amorphous particles; hermetic sealed packages |
| 04/01/2004 | US20040062718 Particles for inhalation having sustained release properties |
| 04/01/2004 | US20040062717 Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols |